The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)

Inclusion Criteria

• •Adenocarcinoma of the prostate.
• •mCRPC setting, with testosterone level \< 50 ng/dl or 1.7 nmol/l.
• •Oligoprogressive disease diagnosed on PSMAscan; defined as the progression of pre-existing metastatic disease, and/or the appearance of new metastases and/or the appearance of a local relapse with a maximum of 3 lesions in total.
• •Patients currently treated with ADT, whether combined with another systemic treatment such as ARTA, chemotherapy.
• •For patients treated with chemotherapy, the course should be completed or stopped before start MORT - In case of treatment with ARTA, a minimal of 3 months response (PSA or clinical response).
• •WHO performance status 0-2.
• •Age \> = 18 years old.
• •Patiënt should be presented at the multidisciplinary tumor board of the local hospital in which the therapy will be given.
• •Before patiënt registration, written informed consent must be given according to ICH/GCO and national/local regulations.